# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday Septembe...
Gainers
Gainers
On Tuesday, 210 companies reached new 52-week lows.
Gainers BioNexus Gene Lab Corp (NASDAQ: BGLC) shares surged 50.1% to $7.31 in pre-market trading. BioNexus Gene Lab reported...